Last week, I had the opportunity to conduct a panel discussion at the national ICON (Indian Co-operative Oncology Network) conference on an increasingly important topic in modern breast cancer care: axillary de-escalation.
The discussion reflected a major shift happening in oncology today.
For decades, breast cancer surgery often followed the philosophy that “more surgery means better cancer control.” But advances in cancer biology, chemotherapy, targeted therapy, radiation therapy, and imaging have changed that thinking dramatically.
Today, doctors are asking a different question:
And increasingly, evidence shows that less surgery can achieve maintain the same cancer cure rates while significantly improving quality of life.
The axilla is the armpit region where lymph nodes are located.
These lymph nodes are important in breast cancer because they are one of the first places cancer cells may spread. Traditionally, surgeons often removed large numbers of lymph nodes through a procedure called axillary lymph node dissection (ALND).
While effective, ALND can leave many patients with long-term side effects such as:
For many years, these complications were considered unavoidable.
Now, that is changing.
Axillary de-escalation means reducing the extent of surgery in the armpit area whenever it is safe to do so.
Importantly, this does not mean compromising cancer treatment.
It means identifying patients who can avoid more aggressive surgery without affecting survival or cancer control.
The focus is shifting from “maximum surgery” to “precision treatment.”
A very important development in modern breast cancer care is that de-escalation is now happening across multiple clinical situations.
Earlier, even a small amount of cancer in the lymph nodes often led to complete axillary dissection.
Today, many patients with limited lymph node involvement can safely avoid extensive node removal, especially when they are also receiving radiation and systemic therapy.
This has been one of the biggest practice-changing developments in breast cancer surgery over the past decade.
Many patients now receive chemotherapy or targeted therapy before surgery (called neoadjuvant therapy).
In some patients, the cancer in the lymph nodes disappears completely after treatment.
This has opened the door to less aggressive surgery afterward.
Instead of automatically removing all lymph nodes, surgeons may selectively remove only the previously involved nodes and key sentinel nodes — an approach known as targeted axillary dissection (TAD).
The goal is to accurately assess response while minimizing long-term complications.
We are now studying whether certain low-risk patients may safely avoid even sentinel lymph node surgery.
This is especially relevant in:
Modern radiation therapy has also changed the equation.
In some situations, radiation can control microscopic disease in the axilla without requiring extensive surgical clearance.
This allows patients to avoid the added morbidity of larger operations while still maintaining excellent cancer outcomes.
For patients, avoiding unnecessary surgery can mean:
As cancer survival improves, these long-term outcomes matter more than ever.
Perhaps the most important takeaway from the discussion was this:
Modern oncology is no longer about doing the biggest operation possible.
It is about combining surgery, medical oncology, radiation oncology, imaging, and pathology in a smarter and more individualized way.
It is important to remember that axillary lymph node dissection still remains necessary and appropriate in many patients. Earlier approaches were based on the best available evidence of their time and played a major role in improving breast cancer outcomes. What is changing today is not that previous treatment was “wrong,” but that advances in cancer care now allow us to safely individualize treatment better than before.
The future – and increasingly the present – of cancer care lies in personalization.
